Acadia Pharmaceuticals (ACAD) Net Cash Flow (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Net Cash Flow of $104.5 million for Q1 2026, up 202.56% year-over-year from $34.5 million in Q1 2025, and up 227.53% quarter-over-quarter from -$81.9 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Net Cash Flow (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $104.5 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 202.56% year-over-year to $104.5 million; the TTM figure through Mar 2026 stood at $63.5 million (up 295.74% YoY), while the FY2025 annual figure was -$142.8 million, down 206.58% from the prior year.
- Net Cash Flow for Q1 2026 stood at $104.5 million, up from -$81.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $176.1 million in Q1 2023, with the low at -$180.6 million in Q2 2023.
- The 5-year median for Net Cash Flow is $4.4 million (2025), against an average of $8.1 million.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow soared 366.79% in 2022, then slumped 733.51% in 2025.
- Acadia Pharmaceuticals' Net Cash Flow stood at -$40.0 million in 2022, then jumped by 326.26% to $90.5 million in 2023, then surged by 81.82% to $164.5 million in 2024, then sank by 149.81% to -$81.9 million in 2025, then soared by 227.53% to $104.5 million in 2026.
- Business Quant data shows ACAD's Net Cash Flow at $104.5 million in Q1 2026, -$81.9 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 102.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.75 Mn |
| Jun 30, 2026 | 102.75 Mn |
| Mar 31, 2026 | 104.49 Mn |
| Mar 31, 2026 | 104.49 Mn |
| Dec 31, 2025 | -81.93 Mn |
| Dec 31, 2025 | -81.93 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Jun 30, 2025 | 36.62 Mn |
| Jun 30, 2025 | 36.62 Mn |
| Mar 31, 2025 | -101.89 Mn |
| Mar 31, 2025 | -101.89 Mn |
| Dec 31, 2024 | 164.50 Mn |
| Dec 31, 2024 | 164.50 Mn |
| Sep 30, 2024 | -18.94 Mn |
| Sep 30, 2024 | -18.94 Mn |
| Jun 30, 2024 | -27.61 Mn |
| Jun 30, 2024 | -27.61 Mn |
| Mar 31, 2024 | 16.08 Mn |
| Mar 31, 2024 | 16.08 Mn |